Simulations Plus, Inc.

  • Market Cap: Micro Cap
  • Industry: Software Products
  • ISIN: US8292141053
USD
20.49
0.96 (4.92%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Simulations Plus, Inc. stock-summary
stock-summary
Simulations Plus, Inc.
Software Products
Simulations Plus, Inc. is a developer of drug discovery and development software for mechanistic modeling and simulation, for machine-learning-based prediction of properties of molecules from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. The Company offers its products and services through two business segments, which include Simulations Plus, Inc. and Cognigen Corporation. Cognigen Corporation is the subsidiary of the Company. Its pharmaceutical/chemistry software is used by various companies, such as pharmaceutical, biotechnology, agrochemical, and food industry companies and to regulatory agencies for use in the conduct of industry-based research. Its clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamics modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions.
Company Coordinates stock-summary
Company Details
42505 10th St W , LANCASTER CA : 93534-7059
stock-summary
Tel: 1 661 72377231 661 7237723
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 54 Schemes (45.5%)

Foreign Institutions

Held by 74 Foreign Institutions (10.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Walter Woltosz
Chairman of the Board
Dr. Lisa LaVange
Independent Director
Dr. John Paglia
Independent Director
Dr. David Ralph
Independent Director
Dr. Daniel Weiner
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
20 Million
(Quarterly Results - May 2025)
Net Profit:
-67 Million
stock-summary
Industry

Software Products

stock-summary
Market cap

USD 285 Million (Micro Cap)

stock-summary
P/E

107.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.23

stock-summary
Return on Equity

10.05%

stock-summary
Price to Book

2.30